Application of Functional Renal MRI to Improve Assessment of Chronic Kidney Disease
- Conditions
- Chronic Kidney Diseases
- Interventions
- Diagnostic Test: Multiparametric renal MRI
- Registration Number
- NCT04238299
- Brief Summary
Research question: Can multiparametric renal Magnetic Resonance Imaging (MRI) provide structural and functional assessment of the kidneys to deliver prognostic information and guide treatment options in chronic kidney disease (CKD)?
Aims and objectives:
1. To establish a multiparametric renal MRI protocol in CKD cohorts.
2. To use multiparametric MRI to characterise people with and without CKD progression.
3. To compare multiparametric renal MRI with 'gold-standard' renal biopsy to determine pathological processes of CKD progression that are detectable by MRI.
- Detailed Description
The study will have three stages.
Stage 1: 45 people with CKD from nine UKRIN centres will undergo multiparametric MRI to test patient tolerance, data completeness and central data collection processes.
Stage 2: A multicentre, prospective cohort study of 450 people with CKD, collecting multiparametric renal MRI at baseline and 2 years. Long-term outcomes will be determined with efficient tracking of kidney failure events via the UK Renal Registry at 5 and 10 years.
Stage 3: A mechanistic sub-study of 45 patients (from Stage 2) who have had a routine renal biopsy. Detailed comparisons will be made between multiparametric MRI and histopathological changes. Tissue blocks will undergo quantitative analysis of fibrosis, capillary density and inflammation using immunohistochemistry techniques.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 450
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Main study cohort Multiparametric renal MRI Patients with CKD recruited from specialist nephrology clinics
- Primary Outcome Measures
Name Time Method CKD progression 10 years kidney failure (doubling of serum creatinine, eGFR\<15ml/min or RRT) OR a 40% decline in eGFR
- Secondary Outcome Measures
Name Time Method Kidney failure events 10 years Doubling of serum creatinine, eGFR\<15ml/min or RRT
40% decline in eGFR from baseline 10 years AKI events 4 years AKI as per KDIGO serum creatinine criteria
eGFR trajectory 2 years (ml/min/yr)
Cardiovascular events 4 years All cause mortality 10 years
Trial Locations
- Locations (1)
Royal Derby Hospital
🇬🇧Derby, Derbyshire, United Kingdom